JCR Pharmaceuticals Co., Ltd.
4552.T · JPX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | ¥15,621,000 | ¥13,180,000 | ¥13,196,000 | ¥15,513,000 |
| Short-Term Investments | ¥0 | ¥0 | ¥0 | ¥0 |
| Receivables | ¥13,645,000 | ¥13,326,000 | ¥12,236,000 | ¥15,179,000 |
| Inventory | ¥23,412,000 | ¥22,714,000 | ¥21,758,000 | ¥24,028,000 |
| Other Curr. Assets | ¥3,155,000 | ¥3,433,000 | ¥3,866,000 | ¥3,022,000 |
| Total Curr. Assets | ¥55,833,000 | ¥52,653,000 | ¥51,056,000 | ¥57,742,000 |
| Property Plant & Equip (Net) | ¥37,131,000 | ¥37,237,000 | ¥37,410,000 | ¥31,702,000 |
| Goodwill | ¥0 | ¥0 | ¥0 | ¥0 |
| Intangibles | ¥2,705,000 | ¥2,826,000 | ¥2,960,000 | ¥3,094,000 |
| Long-Term Investments | ¥10,404,000 | ¥11,094,000 | ¥9,629,000 | ¥11,648,000 |
| Tax Assets | ¥0 | ¥0 | ¥2,985,000 | ¥0 |
| Other NC Assets | ¥2,980,000 | ¥3,527,000 | ¥815,000 | ¥1,331,000 |
| Total NC Assets | ¥53,220,000 | ¥54,684,000 | ¥53,799,000 | ¥47,775,000 |
| Other Assets | ¥2,000 | ¥0 | ¥0 | ¥0 |
| Total Assets | ¥109,055,000 | ¥107,337,000 | ¥104,855,000 | ¥105,517,000 |
| Liabilities | – | – | – | – |
| Payables | ¥1,052,000 | ¥961,000 | ¥590,000 | ¥1,321,000 |
| Short-Term Debt | ¥28,455,000 | ¥28,155,000 | ¥26,055,000 | ¥20,242,000 |
| Tax Payable | ¥365,000 | ¥0 | ¥0 | ¥0 |
| Deferred Revenue | ¥0 | ¥0 | ¥0 | ¥0 |
| Other Curr. Liab. | ¥17,636,000 | ¥16,296,000 | ¥16,091,000 | ¥16,902,000 |
| Total Curr. Liab. | ¥47,508,000 | ¥47,393,000 | ¥43,988,000 | ¥39,099,000 |
| LT Debt | ¥11,650,000 | ¥11,950,000 | ¥12,050,000 | ¥12,150,000 |
| Deferred Rev, NC | ¥0 | ¥0 | ¥0 | ¥0 |
| Deferred Tax Liab, NC | ¥0 | ¥0 | ¥0 | ¥0 |
| Other NC Liab. | ¥1,380,000 | ¥1,378,000 | ¥1,380,000 | ¥1,301,000 |
| Total NC Liab. | ¥13,030,000 | ¥13,328,000 | ¥13,430,000 | ¥13,451,000 |
| Other Liabilities | ¥0 | ¥0 | ¥0 | ¥0 |
| Cap. Leases | ¥0 | ¥0 | ¥0 | ¥0 |
| Total Liabilities | ¥60,538,000 | ¥60,721,000 | ¥57,418,000 | ¥52,550,000 |
| Equity | – | – | – | – |
| Pref Stock | ¥0 | ¥0 | ¥0 | ¥0 |
| Common Stock | ¥9,061,000 | ¥9,061,000 | ¥9,061,000 | ¥9,061,000 |
| Retained Earnings | ¥31,681,000 | ¥29,424,000 | ¥31,191,000 | ¥35,374,000 |
| AOCI | ¥2,009,000 | ¥2,439,000 | ¥1,460,000 | ¥2,814,000 |
| Other Equity | ¥3,000 | ¥3,000 | ¥5,000 | ¥5,000 |
| Total Equity | ¥48,154,000 | ¥46,264,000 | ¥47,043,000 | ¥52,576,000 |
| Supplemental Information | – | – | – | – |
| Minority Interest | ¥361,000 | ¥350,000 | ¥392,000 | ¥396,000 |
| Total Liab. & Tot. Equity | ¥108,692,000 | ¥107,335,000 | ¥104,855,000 | ¥105,517,000 |
| Net Debt | ¥24,484,000 | ¥26,925,000 | ¥24,909,000 | ¥16,879,000 |